Oat Elicitor Treatment for Higher Avenanthramide Content

The patent applies preliminary action by treating oat seeds with elicitors (methyl jasmonate, abscisic acid, or their combinations) during the early germination stage before the oats reach maturity. This preliminary treatment primes the plants to produce higher levels of avenanthramides throughout their development, resolving the contradiction by introducing a simple pre-treatment step that significantly boosts the final avenanthramide content without complicating the overall cultivation process

The patent utilizes parameter changes by modifying the chemical environment during germination through the application of specific elicitors at controlled concentrations. By changing the chemical parameters (introducing methyl jasmonate or abscisic acid), the plant's metabolic pathway is altered to prioritize avenanthramide synthesis, thereby increasing the quantity of this valuable compound while maintaining a relatively simple cultivation framework

The patent applies parameter changes by optimizing the concentration and timing of elicitor application. By carefully controlling the dosage (e.g., specific ranges of methyl jasmonate or abscisic acid) and the stage of application during germination, the system achieves high avenanthramide production while minimizing the amount of elicitor required, thus reducing overall production costs

The patent uses elicitors as intermediary substances that act as signals to trigger the plant's internal avenanthramide biosynthesis pathway. These intermediaries (methyl jasmonate, abscisic acid) are applied in small amounts to activate the plant's own production mechanisms, rather than requiring large inputs of expensive avenanthramide precursors or alternative costly production methods

The patent applies preliminary action by conducting the elicitor treatment during the germination and early seedling stages, when the plant's metabolic activity is high and responsive to environmental signals. This timing ensures that the energy investment in the treatment yields maximum returns in terms of avenanthramide accumulation during subsequent growth phases, optimizing the energy-to-product ratio

The patent utilizes parameter changes by optimizing the concentration, frequency, and timing of elicitor application to maximize gene expression efficiency. By adjusting these parameters, the system enhances the expression of avenanthramide biosynthetic genes in a energy-efficient manner, avoiding excessive energy consumption while still achieving significant increases in avenanthramide production